Acne

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.

Experts discussed laser and light-based therapies for acne, rosacea, hyperpigmentation, and inflammatory skin diseases.

A new qualitative analysis revealed which type of content on acne is trending on the social media platform and how clinicians should respond.

Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.

The top videos under the hashtag, #spironolactone” had low scores on the mDISCERN and GQS scales, according to Adam Friedman, MD, FAAD, senior author of the study.

This review of the latest dermatologic studies includes insights into the efficacy of nutraceuticals in noncystic acne, the role of antimicrobial peptides in the skin barrier, and more.

Patients saw improvement in hydration, sebum, erythema, and scarring after just 3 treatment sessions.

As a part of his presentation at Winter Clinical Miami, Del Rosso discussed new and emerging therapies for acne vulgaris.

Although HA and other methods are safe, more reliable data is needed to determine which is most effective.

The addition of a dermocosmetic cleanser and moisturizer also lessened the adverse events commonly associated with retinoid use.

Researchers found emotional resilience can mitigate acne's psychological and social challenges.

A recent systemic review found FRM to be an effective treatment modality on its own for managing facial acne scars.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in acne this year.

Join Dermatology Times’ quarterly editor in chief Shanna Miranti, MPAS, PA-C, in a look back at acne milestones in 2024 such as topical clindamycin, adapalene, and benzoyl peroxide gel (Cabtreo).

Researchers noted higher correlations in those who are prone to severe acne and post acne erythema (PAE).

Researchers stated that therapy represents a “valuable nonpharmacological intervention that offers an innovative therapeutic alternative” for acne treatment.

Read more about acne treatment tips shared at the 2024 SDPA Fall Conference by experts such as Shanna Miranti, MPAS, PA-C, and Hilary Baldwin, MD.

These findings further suggest the implications of acne vulgaris treatment on the skin barrier.

Research suggested acne is primarily inflammatory, occurring even in unaffected skin, redefining its pathophysiology.

At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted the superiority of branded acne therapies, the necessity of tailored regimens, and the value of structured PA education.

Take this quiz to see if you are leveraging the latest research in acne treatment.

At the SDPA Fall Conference, Miranti emphasized the importance of targeted, comprehensive acne therapies and inspired attendees to embrace pediatric dermatology as a rewarding subspecialty.

A poster presented at the 2024 SDPA Fall Conference demonstrated that clascoterone cream remains stable when paired with commonly prescribed acne topicals, supporting its role in multimodal therapy.

The study demonstrated significant reductions in inflammatory and non-inflammatory lesions for Hispanic patients using CAB gel.

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.

Learn more about the in-depth topics covered in the October 2024 acne supplement of Dermatology Times.

The clinical trial showed promising results for patients who used probiotics as an accompanying treatment.

The recent meta-analysis revealed comparable efficacy in treating acne vulgaris and was presented at Fall Clinical 2024.